KPTI - Karyopharm Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
23,003
30,336
1,605
154
250
Cost of Revenue
-
-
-
-
0
Gross Profit
-
-
-
-
250
Operating Expenses
Research Development
129,651
161,372
107,273
86,938
97,744
Selling General and Administrative
95,803
48,847
24,870
23,948
21,582
Total Operating Expenses
225,454
210,219
132,143
110,886
119,326
Operating Income or Loss
-203,464
-179,883
-130,538
-110,732
-119,076
Interest Expense
6,375
2,493
-
0
-
Total Other Income/Expenses Net
-49
-33
-81
10
-2
Income Before Tax
-209,098
-178,381
-128,921
-109,438
-118,181
Income Tax Expense
55
26
63
139
-
Income from Continuing Operations
-209,153
-178,407
-128,984
-109,577
-118,181
Net Income
-209,153
-178,407
-128,984
-109,577
-118,181
Net Income available to common shareholders
-209,153
-178,407
-128,984
-109,577
-118,181
Reported EPS
Basic
-
-3.14
-2.81
-2.92
-3.32
Diluted
-
-3.14
-2.81
-2.92
-3.32
Weighted average shares outstanding
Basic
-
56,800
45,900
37,523
35,620
Diluted
-
56,800
45,900
37,523
35,620
EBITDA
-
-175,153
-129,825
-108,721
-118,442